Cargando…

Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?

SIMPLE SUMMARY: This study examined the real-world experience and occurrence of immune-related adverse events (irAEs) under cancer checkpoint immunotherapy, and the relationship between its treatment rechallenge status and their impact on clinical outcomes. The current study demonstrates that immune...

Descripción completa

Detalles Bibliográficos
Autores principales:	Albandar, Heidar J., Fuqua, Jacob, Albandar, Jasim M., Safi, Salahuddin, Merrill, Samuel A., Ma, Patrick C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956829/ https://www.ncbi.nlm.nih.gov/pubmed/33673446 http://dx.doi.org/10.3390/cancers13050989

Ejemplares similares

Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge
por: Vaddepally, Raju, et al.
Publicado: (2022)

Occurrence of Possible Rheumatologic Immune-Related Adverse Events (rh-irAEs) Associated with Immune Checkpoint Inhibitor (ICI) Therapy
por: Anjohrin, Suzanne, et al.
Publicado: (2021)

Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
por: Daban, A, et al.
Publicado: (2023)

Editorial: Immune-related adverse Events (irAEs) of biopharmaceuticals
por: Batista-Duharte, Alexander, et al.
Publicado: (2023)

Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors
por: Teng, Yi-Shan, et al.
Publicado: (2023)

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
por: Kumar, Vivek, et al.
Publicado: (2017)

Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
por: Kumar, Vivek, et al.
Publicado: (2017)

4401 Incidence, management, and outcomes of immune-related adverse events (irAEs): an analysis of a multidisciplinary toxicity team for cancer immunotherapy related irAEs
por: Balaji, Aanika, et al.
Publicado: (2020)

Reader Comment Regarding “Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management”
por: Sauder, Maxwell, et al.
Publicado: (2021)

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
por: Naidoo, Jarushka, et al.
Publicado: (2023)

Development of an eHealth Tool for Capturing and Analyzing the Immune-related Adverse Events (irAEs) in Cancer Treatment
por: Moradian, Saeed, et al.
Publicado: (2023)

BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma
por: Labadie, Brian W., et al.
Publicado: (2019)

The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
por: Ke, Wanhai, et al.
Publicado: (2020)

Immunotherapy-related adverse events (irAEs): extraction from FDA drug labels and comparative analysis
por: Wang, QuanQiu, et al.
Publicado: (2018)

Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies
por: Liu, Jing, et al.
Publicado: (2014)

Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis
por: Zhang, Dongyu, et al.
Publicado: (2021)

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
por: Tarhini, Ahmad A, et al.
Publicado: (2021)

Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs
por: Eschweiler, Simon, et al.
Publicado: (2022)

Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service
por: Abu-Shawer, Osama, et al.
Publicado: (2020)

Co Treatment With Biologic Agents and Immunotherapy in the Setting of irAEs of Difficult Management
por: Robles-Alonso, Virginia, et al.
Publicado: (2022)

Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events
por: Isik, Busra, et al.
Publicado: (2021)

Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis
por: Gao, Wen, et al.
Publicado: (2022)

Correction: Zhang et al. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers 2021, 13, 6109
por: Zhang, Dongyu, et al.
Publicado: (2022)

Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer
por: Allouchery, Marion, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
por: Bylsma, Sophia, et al.
Publicado: (2022)

Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy
por: Haanen, John, et al.
Publicado: (2020)

Correction: Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer
Publicado: (2021)

Bell's palsy during rechallenge of immune checkpoint inhibitor
por: Takemura, Kohji, et al.
Publicado: (2023)

Recurrence of Hypophysitis After Immune Checkpoint Inhibitor Rechallenge
por: Park, Benjamin C, et al.
Publicado: (2022)

Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis
por: Ai, Qi, et al.
Publicado: (2022)

Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events
por: Siddiqui, Bilal A, et al.
Publicado: (2021)

Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced Adrenal insufficiency
por: Xiang, Jing, et al.
Publicado: (2023)

Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients’ Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC)
por: Nardin, Charlée, et al.
Publicado: (2023)

Rechallenge in Immune Checkpoint Inhibitors Associated Renal Tubular Acidosis
por: Shah, Chintan V., et al.
Publicado: (2023)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
por: Naimi, Adel, et al.
Publicado: (2022)

Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI) Versus Non-ICI Era: A Population-Based Study
por: Safi, Mohammed, et al.
Publicado: (2021)

Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis
por: Zhao, Qing, et al.
Publicado: (2021)

Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors
por: Chennamadhavuni, Adithya, et al.
Publicado: (2022)

Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature
por: Casselman, Pauline, et al.
Publicado: (2023)

Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
por: Scheiner, Bernhard, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_74ggugsua6lqbptgh5sl617vnd